

## **SURAT KETERANGAN**

Nomor: 1888/UNUSA-LPPM/Adm.I/IX/2022

Lembaga Penelitian dan Pengabdian Kepada Masyarakat (LPPM) Universitas Nahdlatul Ulama Surabaya menerangkan telah selesai melakukan pemeriksaan duplikasi dengan membandingkan artikel-artikel lain menggunakan perangkat lunak **Turnitin** pada tanggal 23 Februari 2022.

Judul : The Relationship Of Gentamycin Antibiotic Exposure To:  
Escherichia Coli Bacteria Resistant To Antibiotic Gentamycin And  
Escherichia Coli ESBL In Vitro

Penulis : Diah Retno Kusumawati

No. Pemeriksaan : 2022.09.19.749

Dengan Hasil sebagai Berikut:

**Tingkat Kesamaan diseluruh artikel (*Similarity Index*) yaitu 6%**

Demikian surat keterangan ini dibuat untuk digunakan sebagaimana mestinya.

Surabaya, 19 September 2022

Ketua LPPM



UNUSA  
LPPM

Achmad Syafiuddin, Ph.D

NPP: 20071300

**LPPM Universitas Nahdlatul Ulama Surabaya**

Website : [lppm.unusa.ac.id](http://lppm.unusa.ac.id)

Email : [lppm@unusa.ac.id](mailto:lppm@unusa.ac.id)

Hotline : 0838.5706.3867

# The Relationship Of Gentamycin Antibiotic Exposure To: Escherichia Coli Bacteria Resistant To Antibiotic Gentamycin And Escherichia Coli ESBL In Vitro

*by* KusumawatiDiah Retno

---

**Submission date:** 23-Feb-2022 12:54PM (UTC+0700)

**Submission ID:** 1768954607

**File name:** 2138-Article\_Text-12598-1-10-20220127.pdf (493.87K)

**Word count:** 3210

**Character count:** 18047



## The Relationship of Gentamicyn Antibiotic Exposure To: *Escherichia coli* Bacteria Resistant to Antibiotic Gentamicyn and *Escherichia coli* ESBL In Vitro

Diah Retno Kusumawati<sup>1,2\*</sup>

<sup>1</sup> Clinical Medical Science Master Degree, Faculty of Medicine, Airlangga University Surabaya

<sup>2</sup> Departement of Microbiology, Faculty of Medicine, University of Nahdlatul Ulama Surabaya

\*Corresponding author:

### ARTICLE INFO

#### Keywords:

*Escherichia coli*,  
Susceptible,  
Resistant,  
Gentamycin,  
ESBL

Submission:

June 4<sup>th</sup>, 2021

Review:

December 5<sup>th</sup>,

2021

Publish:

January 20<sup>th</sup>, 2022

### ABSTRACT

**Introduction:** The development of bacteria that have been resistant to antibiotics can complicate the treatment process. Either causes of antibiotic resistance is inappropriate use of antibiotics. *Gentamycin* is an aminoglycoside-derived antibiotic which its role is very significant for Gram-negative bacteria. Repeated use of *Gentamycin* antibiotics can cause changes the effectiveness of *Gentamycin* so that non ESBL-*Gentamycin* susceptible *Escherichia coli* will change into ESBL-*Gentamycin* resistant *Escherichia coli*. This study aims to prove that repeated exposure to *Gentamycin* in vitro will change non ESBL-*Gentamycin* susceptible *Escherichia coli* into ESBL *Gentamycin* resistant *Escherichia coli*.

**Methods:** This was an experimental study with 30 samples of non ESBL-*Gentamycin* susceptible *Escherichia coli* isolates identified from the Phoenix. Non ESBL-*Gentamycin* susceptible *Escherichia coli* was tested by giving exposure to *Gentamycin* for 14 days, then ESBL screening was tested by *Cefotaxime* exposure to the results of *Gentamycin* exposure.

**Result and Discussion:** There were 4 isolates of *Escherichia coli* which experienced changes in phenotype into *Gentamycin* resistant *Escherichia coli*. The rest of it still susceptible to *Gentamycin* on days 2, 4 and 10. Furthermore, the *Escherichia coli* isolates were both susceptible to *Gentamycin* and those that had phenotypic changes become resistant to *Gentamycin* after exposed to *Cefotaxime* as an ESBL screening. There are 8 (26.7%) isolates that are still susceptible to *Cefotaxime* and 18 (60%) isolates that have been transformed into ESBL-*Gentamycin* susceptible *Escherichia coli*. Isolates of 4 (13.3%) *Gentamycin*-resistant *Escherichia coli* are then exposed to *Cefotaxime* and obtained all isolates is resistant to *Cefotaxime*.

**Conclusion:** Repeated exposure of *Gentamycin* for 14 days in vitro was not significantly related to the phenotypic changes of non ESBL-*Gentamycin* susceptible *Escherichia coli* isolates into ESBL-*Gentamycin* resistant *Escherichia coli* ( $P = 0.550$ ,  $\Phi = 0.237$ ).

### Introduction

The development of bacteria that have become resistant to antibiotics can

complicate the treatment process. One of the causes of antibiotic resistance is the inappropriate use of antibiotics. Some resistant bacteria that often appear include

methicillin-resistant *Staphylococcus epidermidis*, *Vancomycin-resistant Enterococci*, Gram-negative bacteria that are resistant to the  $\beta$ -lactam group (Desiyana, 2008).

The use of antibiotics that are not following existing resistance patterns can cause bacterial resistance to an antibiotic. One of the principles behind the emergence and spread of resistance between bacteria is the prevalence of resistance, which is directly proportional to the number of antibiotics used in various treatments. This is illustrated by the increase in antibiotic resistance in several countries that do not limit the use of antibiotics (Elliot *et al.*, 2013). Therefore, it is necessary to make an effort to determine the suitability of using antibiotics based on the results of culture and bacterial sensitivity tests.

*Gentamycin* is an *Aminoglycoside* derivative antibiotic that is very significant, especially because of its role against Gram-negative bacteria. This compound is used for bacteria that are resistant to other antibiotics. The mechanism of *Gentamycin* action is by binding irreversibly to the 30S subunit of the bacterial ribosome which results in inhibiting protein synthesis and causing an incorrect translocation of the genetic code. *Gentamycin* is bactericidal. *Gentamycin* is effective against a wide range of Gram-negative bacterial strains including *Escherichia*, *Enterobacter*,

*Klebsiella*, *Proteus*, and *Pseudomonas* species. For against Gram-positive microorganisms, *Gentamycin* is effective for *Staphylococcus aureus* and *Staphylococcus epidermidis*.

The research conducted by Winarto in 2004 - 2005, regarding the prevalence of ESBL (Extended Spectrum Beta-Lactamase) bacteria from blood specimens at Dr. Kariadi General Hospital, it was stated that the pattern of the effectiveness of *Gentamycin* antibiotics against ESBL bacteria was > 40%. The effectiveness of the antibiotic *Gentamycin* against various kinds of bacteria was varies, which against *Acinetobacter baumannii* by 40%, *E. coli* ESBL 63%, *Klebsiella aerogenes* 70%, *Klebsiella pneumoniae* ESBL 71.5%, and even against *Pseudomonas aeruginosa* by 92.5%, so the authors feel the need to changes research in the effectiveness of the antibiotic *Gentamycin* against *E. coli* ESBL.

The change in sensitivity to *Gentamycin* was influenced by the genes encoding *Acetyltransferase aac (3) - IIa* and *aac (3) - VIa* which in the R. plasmid where if the bacteria were exposed to *Gentamycin* continuously then *Acetyltransferase aac (3) - IIa* and *aac (3) - VIa* will be expressed by releasing the enzyme *N acetyltransferase*. Then the enzyme will influence the bacteria to

change its catch point in the 30S Ribosome sub-unit.

In the plasmid, several other resistant genes are likely to be ESBL coding genes, namely BlaTEM, BlaSHV, and CTX, so that if the *aac* (3) - IIa and *aac* (3) - VIa *Acetyltransferase* genes in plasmids are expressed due to repeated exposure to *Gentamycin*, the ESBL gene will also expressed the bacteria changed, which initially was *Gentamycin* susceptible *E. coli* non-ESBL, which turned into *Gentamycin* resistant producing ESBL *E. coli*.

## Methods

This research is an experimental study by providing treatment and observation of non-ESBL *E. coli* bacteria from urine culture. This study used a pre-post test only design, where the test was conducted at the beginning and the end of the study to see the changes that occurred after the treatment was carried out. The study of the population was clinical isolates of *E. coli* stored from urine specimens in the Clinical Microbiology Unit of Dr. Soetomo Hospital, Surabaya. The research sample was clinical isolate *E. coli* which stored from urine specimens and was susceptible to *Gentamycin* and non-ESBL in the Clinical Microbiology Unit of the Dr. Soetomo Surabaya Hospital from May to August 2019.

So for this study we used 30 isolate of susceptible Gentamicyn non-ESBL *E. coli*. The sample's inclusion criteria are *E. coli* isolate which susceptible to *Ceftazidime*, *Cefotaxime*, *Ceftriaxone*, and *Cefoperazone Sulbactam*; these bacterial isolates have been identified and tested for antimicrobial sensitivity using an automatic technique (Phoenix TM or Vitek 2); *E. coli* which susceptible to *Gentamycin*. And the exclusion criteria is stored *E. coli* isolates that do not grow.

A sampling of bacterial clinical isolates from urine specimens was carried out using a consecutive sampling technique. Each sample that meets the research criteria is taken so that the required sample size is met. The research was conducted at the Clinical Microbiology Unit of Dr. Soetomo Hospital, Surabaya. From May 2019 - August 2019. The main material that used in this research was non-ESBL *E. coli* bacterial, isolates stored from the Clinical Microbiology Unit of Dr. Soetomo Surabaya. Additional materials used in this study were Mueller-Hinton agar medium, 30 µg *Cefotaxime* antibiotic disc, and 10 µg *Gentamycin*.

## Result and Discussion

The samples of this study were 30 *Escherichia coli* isolates obtained from clinical specimens taken by consecutive sampling. From May 2019 to August 2019

samples were collected. *E. coli* isolates that were susceptible to *Gentamycin* non ESBL obtained from the automatic phoenix machine were retested using the Kirby-Bauer method. The re-sensitivity test using the Kirby-Bauer antibiotic disk diffusion method was carried out to equate the method used during the ESBL screening and confirmation test and to the sensitivity of *Gentamycin*.

All isolates that met the inclusion-exclusion criteria were repeatedly exposed to *Gentamycin* (CN) discs for 14 days. The exposure was carried out every day in agar media containing MH agar using *Gentamycin* discs with a maximum length of study of 1-14 days. If within 1-14 days of the study, a positive result of *Gentamycin*

resistance is obtained, then it will be continued by giving *Cefotaxime* exposure to screen for ESBL. At the beginning of the research, after the *E. coli* obtained from the automatic phoenix machine was then retested using the Kirby-Bauer method, it was found that 30 (100%) *E. coli* isolates were susceptible to *Gentamycin* and susceptible to *Cefotaxime*.

Then the 30 *E. coli* isolates were exposed to *Gentamycin* discs for 1-14 days. Every day, it was observed whether there were phenotypic changes in the *E. coli* isolate. Isolates that were still resistant to *Gentamycin* were replanted on MH agar media and then exposed to *Gentamycin* discs. This was done continuously for 14 days.

**Table 1. *E. coli* Resistance to Exposure of *Gentamycin* 10ug with Kirby-Bauer Method (total n= 30)**

No	Exposure	Exposure of <i>Gentamycin</i> 10µg	
		Sensitivity	Resistance
1	Day - 2	1 (3,3%)	29 (96,7%)
2	Day - 4	1 (3,3%)	28(93,3%)
3	Day - 10	2 (6,7%)	26(86,7%)

From the research, it was found that the *E. coli* phenotype changes from *Gentamycin* susceptible to *Gentamycin* resistance. These changes occurred on day 2 of 1 isolate of *E. coli* (3.3%), day 4 of 1

isolate (3.3%), and day 10 of 2 isolates of *E. coli* (6.7%). The next stage is that *E. coli* which has undergone a phenotypic change is tested using a Cefotaxim disc as an ESBL screening.

**Table 2. *E. coli* Gentamycin Resistance to Exposure of Cefotaxime 30ug with Kirby-Bauer Method (total n= 30)**

No	Exposure	Exposure of Cefotaxim 30 µg	
		Sensitivity	Resistance
1	Day - 1	0 (0%)	4 (100%)

The results showed that 4 *E. coli* isolates that had changed their phenotypes to Gentamycin-resistant *E. coli* were also phenotypically changed to *E. coli* ESBL. Furthermore, after the completion of the

study time of 14 days, 26 isolates of *E. coli* that were susceptible to Gentamycin were exposed to Cefotaxim discs as ESBL screening.

**Table 3. *E. coli* suseptibel Gentamycin Resistance to Exposure of Cefotaxim 30µg with Kirby-Bauer Method (total n=26)**

No	Exposure	Paparant Gentamycin 10µg	
		Sensitivity	Resistance
1	Day - 1	8 (30,8%)	18 (69,2%)

The results showed that 8 isolates of *E. coli* non-ESBL (30.8%) and 18 isolates of *E. coli* (69.2%) had phenotypic changes to *E. coli* ESBL. From the statistics, it was found that there was no significant relationship between Gentamycin susceptible *E. coli* non-ESBL and Gentamycin ESBL resistant *E. coli* ( $P = 0.550$ ,  $\Phi = 0.237$ ).

In this study, 30 *E. coli* isolates were exposed to Gentamycin. The results showed that *E. coli* isolates had phenotypic changes from Gentamycin susceptible *E. coli* to Gentamycin resistant *E. coli*. This change occurred on day 2 in 1 isolate, day 4 in 1 isolate and day 10 in 2 isolates. So in total, 4 *E. coli* isolates that had phenotypic

changes from Gentamycin susceptible *E. coli* to Gentamycin resistant *E. coli*.

This is related to the ability of bacteria to adapt to their environment. The presence of Gentamycin in the environment makes *E. coli* try to spread the gene coding for Gentamycin resistance via plasmids. Bacterial cells can respond to antibiotics so that they become resistant. These mechanisms include a decrease in the concentration of intracellular antibiotics of bacteria, changes in antibiotic molecules, and changes in antibiotic targets of action (Munita *et al.*, 2016).

In this study, the results showed that *E. coli* experienced a phenotypic change from Gentamycin susceptible *E. coli* to Gentamycin resistant *E. coli*. This is due to

the gene encoding the resistance code for *Gentamycin* Antibiotics, namely Aseltitransferase  $\alpha$ ac (3) - IIa and  $\alpha$ ac (3) - VIa which are in plasmid R, if bacteria are exposed to *Gentamycin* continuously then Aseltitransferase  $\alpha$ ac (3) - IIa and  $\alpha$ ac (3) - VIa will be expressed by releasing the enzyme N acetyltransferase. Then the enzyme will influence the bacteria to change their catch point in the 30S Ribosome sub-unit.

From the research, it was found that 4 *E. coli* isolates experienced phenotypic changes, but the rest remained susceptible to *Gentamycin* because the resistance mechanism of each antibiotic class could be different from other groups. Some researchers mention cross-resistance between different antibiotic classes (Talan et al., 2016). Furthermore, both *E. coli* isolates that were still susceptible to *Gentamycin* and those who had undergone phenotypic changes to be *Gentamycin* resistant were exposed to *Cefotaxime* as an ESBL screening. The results obtained on exposure to *Gentamycin* susceptible, *E. coli* with *Cefotaxime* obtained have the following results; 8 (30.8%) isolates that were still susceptible to *Cefotaxime* and 18 (69.2%) isolates that had turned into *Gentamycin* ESBL susceptible *E. coli*.

The results of 4 isolates *E. coli* resistant to *Gentamycin* (100%) after being exposed to *Cefotaxime*, all isolates were

resistant to *Cefotaxime*. This is following research conducted by Amin (2017) from the Clinical Microbiology Unit of the Dr. Soetomo Surabaya Hospital, where in this study there was a change in phenotypic properties from 4 (25%) non-ESBL *E. coli* isolates to ESBL *E. coli* after being exposed to Ciprofloxacin. The phenotypic change from *Gentamycin* susceptible *E. coli* non-ESBL to *Gentamycin* ESBL resistant *E. coli* is due to exposure to a class of antibiotics, in this case *Gentamycin* can cause cross-resistance to other antibiotic classes, in this case, the beta-lactam group. Resistant strains can spread the resistant genes that are in their mobile gene to other bacteria horizontally, allowing viable bacteria that initially do not have a resistant gene to turn into a resistant strain. Conjugation is the most frequent gene transfer mechanism (Thacker D James et al., 2012). From the statistics, there was no significant relationship between *Gentamycin* susceptible *E. coli* non-ESBL and *Gentamycin* ESBL resistant *E. coli* after being exposed to *Gentamycin* disk for 14 days ( $P = 0.550$ ,  $\Phi = 0.237$ ).

## Conclusion

The conclusion that can be drawn from the results of this study is that. Repeated exposure to *Gentamycin* for 14 days was not statistically significant to cause changes in the phenotype of non-



ESBL *Gentamycin* susceptible *Escherichia coli* isolates to *Gentamycin*-resistant *Escherichia coli* isolates.

## Reference

- Amin, M. 2017. Perbandingan Antara Paparan Ciprofloxacin Dan Cefotaxime terhadap Timbulnya ESBL Pada *Escherichia coli*, Fakultas Universitas Airlangga Surabaya
- Brusch, J.L. 2015. Catheter-Related Urinary Tract Infection. Diunduh dari <http://emedicine.medscape.com/article/2040035-overview>  
Accessed at 5 Oktober 2018
- CLSI M100-S24, 2014. *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement* pp.111-2
- Dolejska, M., Villa, L., Hasman, H., Hansen, L., Carottoli, A. 2013. Characterization of IncN plasmids carrying bla<sub>CTX-M-1</sub> and qnr genes in *Escherichia coli* and *Salmonella* from animals, the environment, and humans. In *J. antimicrobe Chemother* 68 pp.333-9
- Elliot, T., Worthington, T., Osman, H and Gill, M. 2013. *Mikrobiologi Kedokteran & Infeksi Edisi 4*. Jakarta : EGC.
- Figuro, L.S.B., Traveso, T. G., Luque, P.B., González, M.D.G., Nieto, A.G., Martín, T.P., Sagrado, M.G., Laita, A.D., Castrillón, J.L.P. 2012. *Epidemiology, Risk Factors and Comorbidity for Urinary Tract Infections Caused by Extended-Spectrum Beta-Lactamase (ESBL) Producing Enterobacteria*.  
[www.medscape.com/viewarticle/769624\\_print](http://www.medscape.com/viewarticle/769624_print) pada 18/5/20168
- Gallo, G dan Puglia, A.M. 2014. Antibiotics and Resistance: A Fatal Attraction. Antibiotics: Target, Mechanisms, and Resistance. Wiley VCH Weinheim Germany pp.73-108
- Hawa, L.C., Susilo, B., and Jayasari, N.E., 2011. Studi Komparasi Inaktivasi *Escherichia coli* dan Perubahan Sifat Fisik Pada Pasteurisasi Susu Sapi Segar Menggunakan Metode Pemanasan dan Tanpa Pemanasan Dengan Kejut Medan Listrik. Jakarta, Indonesia. *J. Teknologi Pertanian*.
- Heyns C.F., 2012. Urinary Tract Infection Associated With Conditions Causing Urinary Tract Obstruction And Stasis, Excluding Urolithiasis And Neuropathic Bladder. *World Journal of Urology* 30(1):77–83
- Jun KI, Koo HL, Kim MK, Kang CK, Kim MJ, Chun SH, Song JS, Kim HS, Kim NJ, Kim EC, et al., 2013. Trends in antibiotic use in a single university hospital. *Korean J Nosocomial Infect Control*.(18):44–50
- Katzung, B.G., Masters, S.B. dan Trevor, A.J., 2014. *Farmakologi Dasar & Klinik*, Vol.2, Edisi 12, Editor Bahasa Indonesia Ricky Soeharsono et al., Penerbit Buku Kedokteran EGC, Jakarta.
- K. Ejrnæs, 2011. *Bacterial Characteristics Of Importance For Recurrent Urinary Tract Infections Caused by Escherichia coli*. Diunduh dari <https://www.ncbi.nlm.nih.gov/pubmed/21466767> accessed at 16 Oktober 2018
- Munita, Jose. M. & Arias, Caesar, A. 2016. Mechanism of Antibiotic Resistance. HHS Public Access Microbiol Spectr. Vol.4(2).

- Osthoff, M., McGuinness, SL., Wagen, AZ., Eisen, DP. 2015. Urinary Tract Infections Due To Extended-Spectrum Beta-Lactamase Producing Gram-Negative Bacteria: Identification Of Risk Factors And Outcome Predictors In An Australian Tertiary Referral Hospital. *International Journal of Infectious Diseases* 34 (2015)pp 79-83
- Paramythiotou, E., Routsis, R. 2016. Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients In *World J Crit Care Med* 5(2): 111-20
- Sanchez, GV., Master, RN., Karlowsky, JA., Bordon, JM. 2012. In vitro antimicrobial resistance of urinary *Escherichia coli* isolates among U.S. outpatients from 2000 to 2010. In *Antimicrob Agents Chemother.* 56(4):2181-3
- Sass, Peter. 2017. *Methods in Molecular Biology Antibiotics Methods and Protocols*, Springer Science+Business Media New York
- Sharma, K.K., Saikia, R., Kotoky, J., Kalita, J.C. & Devi, R. 2011. Antifungal Activity of *Solanum melongena* L., *Lawsonia inermis* L., *Justicia gendarussa* B. (3), 1635-1640.
- Spadafino, J.T., Cohen, B., Liu, J., Larson, E. 2014. Temporal trends and risk factors for extended-spectrum beta-lactamase-producing *Escherichia coli* in adults with catheter-associated urinary tract infections. Diunduh dari <http://link.springer.com/article/10.1186/s13756-014-0039-y>  
Accessed at 4 Oktober 2018
- Talan, DA., Takhar, SS., Krishnadasan, A., Abrahamian, FM., 2016. Fluoroquinolone-Resistant and Extended-Spectrum  $\beta$ -Lactamase-Producing *Escherichia coli* Infections in Patients with Pyelonephritis, United States. *Emerging Infectious Diseases* 22(9); 1594-604
- Thacker D, James., Carol, M Arlett. 2012. *The law of unintended consequences and antibiotics*, Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, USA.
- Tille, PM. 2014. *Bailey & Scott's Diagnostic Microbiology 13<sup>th</sup> ed.* Elsevier St. Louis, Missouri. Pp.307-28
- Todar, K. 2011. Bacterial Resistance to Antibiotics. Todar's online text book of bacteriology. Diunduh dari [http://textbookofbacteriology.net/resantimicrobial\\_3.html](http://textbookofbacteriology.net/resantimicrobial_3.html)  
Accessed at 11 November 2018
- Vardi, M., Kochavi, T., Denekamp, Y., Bitterman, H. 2012. Risk Factors for urinary tract infection caused by enterobacteriaceae with extended-spectrum Beta-lactamase resistance in Patients admitted to internal medicine departments. *IMAJ* (14): 115-8
- Vergidis, P., Patel, R.. 2012. Novel Approaches to the Diagnosis, Prevention and Treatment of Medical Device-Associated Infections. *Infect Dis Clin North Am* 26(1): 173-186
- Walker, KE., Mahon, CR., Lehman, D., Manuselis, G. 2015. *Enterobacteriaceae. In Text book of diagnostic microbiology 5<sup>th</sup> ed.* pp 420-54
- Wiguna, Septi Dian. 2016. *Pola Resistensi Bakteri Terhadap Antibiotik Pada Penderita Infeksi Luka Operasi (ILO) Di Rumah Sakit X Periode Agustus 2013 – Agustus 2015.*

- Program Studi Farmasi Fakultas  
Farmasi Surakarta
- Woodford, N., Turton, J.F., Livermore,  
D.M. 2011. Multi Resistant Gram  
Negative Bacteria: The Role Of  
High-Risk Clones In The  
Dissemination Of Antibiotic  
Resistance. *FEMS Microbiol. Rev*  
35:736–55
- Zeng, X., Lin, J. 2013. Beta-Lactamase  
Induction And Cell Wall  
Metabolism In Gram-Negative  
Bacteria.  
[https://www.ncbi.nlm.nih.gov/pmc/  
articles/PMC3660660/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660660/) accessed at  
20 Oktober 2016

# The Relationship Of Gentamycin Antibiotic Exposure To: Escherichia Coli Bacteria Resistant To Antibiotic Gentamycin And Escherichia Coli ESBL In Vitro

---

ORIGINALITY REPORT

---

6%

SIMILARITY INDEX

3%

INTERNET SOURCES

3%

PUBLICATIONS

2%

STUDENT PAPERS

---

MATCH ALL SOURCES (ONLY SELECTED SOURCE PRINTED)

---

2%

★ e-journal.unair.ac.id

Internet Source

---

---

Exclude quotes      On

Exclude bibliography      On

Exclude matches      < 1%